Cite
HARVARD Citation
Suzuki, H. et al. (2021). Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Japanese journal of clinical oncology. pp. 1287-1297. [Online].